Last updated: April 23, 2026
Who Supplies BENICAR (Olmesartan Medoxomil)?
What companies supply BENICAR’s active ingredient and key manufacturing inputs?
BENICAR is the brand for olmesartan medoxomil, an angiotensin II receptor blocker (ARB). The brand is marketed in the US by Bristol Myers Squibb (BMS). While BENICAR’s label identifies the marketing authorization holder and lists manufacturing sites, it typically does not name the underlying API and intermediate suppliers in a way that is complete for all global sources. The most actionable supply-chain view for BENICAR is therefore organized around: (1) finished-dose manufacturers shown on US labeling and (2) API manufacturers that appear in regulatory filings and related public datasets.
| Finished-dose manufacturers listed for BENICAR (US label-facing supply) |
Product strength (US) |
Finished-dose manufacturing entities shown in publicly indexed labeling |
Typical role |
| BENICAR (olmesartan medoxomil) tablets |
Manufacturer list varies by strength and label revision (site and label updates) |
Finished-dose production / packaging release |
Which suppliers are most visible for BENICAR through regulatory and labeling signals?
Publicly indexed sources for BENICAR supply typically surface suppliers under one of two patterns:
- US labeling “Manufactured for / Distributed by” and manufacturing site statements, which identify the firms responsible for finished-dose manufacturing and release.
- API manufacturer identifiers that appear in regulatory-linked datasets used by market intelligence providers (often via drug master files, DMFs, or supplier listings surfaced through inspections or filing extracts).
Best-evidence supplier set for BENICAR is “finished-dose manufacturers + API DMF-linked firms” rather than a single universal API vendor.
How does BENICAR’s supplier map affect R&D and investment decisions?
What supply-chain risks matter for BENICAR?
| Risk vector |
Impact on BENICAR |
| Multi-site manufacturing |
Dose-level changes can shift supply among facilities without changing the product label identity |
| API-source turnover |
API sourcing changes can alter lead times and compounding schedules for generics and authorized generics |
| Regulatory inspection exposure |
A supplier under scrutiny can constrain capacity, driving volatility in certain strengths |
What contracting structure is typical for an older, branded ARB like BENICAR?
- Brand owner controls global commercial packaging and release strategy
- Finished-dose manufacturing is executed by contract manufacturers at labeled sites
- API supply is handled through DMF-linked qualified sources, often multiple vendors to support continuity
What supplier facts are available from BENICAR’s public brand presence?
Who is the brand/marketing authorization holder for BENICAR?
- Bristol Myers Squibb (BMS) markets BENICAR in the US.
Which public records typically identify BENICAR manufacturing suppliers?
- US prescribing information (package insert) manufacturing statements
- FDA drug labeling repositories and public drug databases
- DMF-linked API supplier listings in regulatory-linked public datasets
Because BENICAR’s detailed manufacturing-site roster is strength- and revision-dependent, the supplier list must be taken from the specific US label version in force at the time of assessment.
Key Takeaways
- BENICAR’s supplier network is best analyzed as brand owner (BMS) + labeled finished-dose manufacturers + DMF-linked API sources rather than a single named supplier.
- The most decision-grade supplier data for BENICAR comes from US labeling manufacturing statements and regulatory-linked API source identifiers.
- Supplier visibility is not uniform across strengths and changes with label revisions, so any procurement or investment view must map supply by strength and current label version.
FAQs
1) Who owns BENICAR?
Bristol Myers Squibb (BMS).
2) Who manufactures BENICAR tablets?
Finished-dose manufacturing is performed by entities named in BENICAR’s US labeling “manufactured for / manufacturing site” sections, with site lists that can differ by strength and label revision.
3) Who supplies the olmesartan medoxomil API?
Olsesartan medoxomil is supplied by API manufacturers that are typically linked via regulatory submissions (DMFs) and reflected in regulatory-linked supplier datasets; the API source set can include multiple qualified vendors.
4) Is the supplier list the same for every BENICAR strength?
No. Manufacturing site and release configurations can vary by strength and label revision.
5) Where do the most reliable supplier names come from?
From BENICAR US prescribing information manufacturing statements and regulatory-linked drug supply datasets.
Sources
[1] FDA. “Drug Label Information for BENICAR (olmesartan medoxomil).” FDA Access Data / labeling repositories.
[2] DailyMed. “BENICAR (olmesartan medoxomil) tablets, for oral use.” DailyMed prescribing information and label manufacturing sections.
[3] FDA. “Drugs@FDA: BENICAR (olmesartan medoxomil).” FDA Drugs@FDA database.
